Top

Published in:

Open Access 01-12-2021 | Metastasis | Research

Patterns of pathologic lymph nodes in anal cancer: a PET-CT-based analysis with implications for radiotherapy treatment volumes

Authors: Anna Frennered, Jonas Scherman, Pamela Buchwald, Anders Johnsson, Hanna Sartor, Sophia Zackrisson, Elin Trägårdh, Martin P. Nilsson

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

This study investigates the patterns of PET-positive lymph nodes (LNs) in anal cancer. The aim was to provide information that could inform future anal cancer radiotherapy contouring guidelines.

Methods

The baseline [18F]-FDG PET-CTs of 190 consecutive anal cancer patients were retrospectively assessed. LNs with a Deauville score (DS) of ≥3 were defined as PET-positive. Each PET-positive LN was allocated to a LN region and a LN sub-region; they were then mapped on a standard anatomy reference CT. The association between primary tumor localization and PET-positive LNs in different regions were analyzed.

Results

PET-positive LNs (n = 412) were identified in 103 of 190 patients (54%). Compared to anal canal tumors with extension into the rectum, anal canal tumors with perianal extension more often had inguinal (P < 0.001) and less often perirectal (P < 0.001) and internal iliac (P < 0.001) PET-positive LNs. Forty-two patients had PET-positive LNs confined to a solitary region, corresponding to first echelon nodes. The most common solitary LN region was inguinal (25 of 42; 60%) followed by perirectal (26%), internal iliac (10%), and external iliac (2%). No PET-positive LNs were identified in the ischiorectal fossa or in the inguinal area located posterolateral to deep vessels. Skip metastases above the bottom of the sacroiliac joint were quite rare. Most external iliac PET-positive LNs were located posterior to the external iliac vein; only one was located in the lateral external iliac sub-region.

Conclusions

The results support some specific modifications to the elective clinical target volume (CTV) in anal cancer. These changes would lead to reduced volumes of normal tissue being irradiated, which could contribute to a reduction in radiation side-effects.

Available only for authorised users

Deshmukh AA, Suk R, Shiels MS, Sonawane K, Nyitray AG, Liu Y, et al. Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001-2015. J Natl Cancer Inst. 2020;112(8):829–38. https://doi.org/10.1093/jnci/djz219.CrossRefPubMed

Guren MG, Aagnes B, Nygård M, Dahl O, Møller B. Rising incidence and improved survival of anal squamous cell carcinoma in Norway, 1987-2016. Clin Colorectal Cancer. 2019;18(1):e96–e103. https://doi.org/10.1016/j.clcc.2018.10.001.CrossRefPubMed

Jin F, Stein AN, Conway EL, Regan DG, Law M, Brotherton JM, et al. Trends in anal cancer in Australia, 1982-2005. Vaccine. 2011;29(12):2322–7. https://doi.org/10.1016/j.vaccine.2011.01.015.CrossRefPubMed

Shiels MS, Kreimer AR, Coghill AE, Darragh TM, Devesa SS. Anal Cancer Incidence in the United States, 1977-2011: distinct patterns by histology and behavior. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1548–56.CrossRef

Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB 3rd, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30(35):4344–51. https://doi.org/10.1200/JCO.2012.43.8085.CrossRefPubMedPubMedCentral

James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013;14(6):516–24. https://doi.org/10.1016/S1470-2045(13)70086-X.CrossRefPubMed

Martin D, Balermpas P, Winkelmann R, Rodel F, Rodel C, Fokas E. Anal squamous cell carcinoma - state of the art management and future perspectives. Cancer Treat Rev. 2018;65:11–21. https://doi.org/10.1016/j.ctrv.2018.02.001.CrossRefPubMed

Bentzen AG, Balteskard L, Wanderås EH, Frykholm G, Wilsgaard T, Dahl O, et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncol. 2013;52(4):736–44.CrossRef

Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86(1):27–33. https://doi.org/10.1016/j.ijrobp.2012.09.023.CrossRefPubMed

10.

Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol. 2014;111(3):330–9. https://doi.org/10.1016/j.radonc.2014.04.013.CrossRefPubMed

11.

The Swedish national care program for anal cancer (in Swedish). https://kunskapsbanken.cancercentrum.se/diagnoser/analcancer/vardprogram/. Accessed 10 Aug 2020.

12.

Mahmud A, Poon R, Jonker D. PET imaging in anal canal cancer: a systematic review and meta-analysis. Br J Radiol. 2017;90(1080):20170370. https://doi.org/10.1259/bjr.20170370.CrossRefPubMedPubMedCentral

13.

Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74(3):824–30. https://doi.org/10.1016/j.ijrobp.2008.08.070.CrossRefPubMed

14.

Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, et al. Australasian gastrointestinal trials group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1455–62. https://doi.org/10.1016/j.ijrobp.2011.12.058.

15.

The Norweigan national care program for anal cancer (in Norweigan). https://www.helsedirektoratet.no/retningslinjer/analkreft-handlingsprogram/Analkreft%20-%20Nasjonalt%20handlingsprogram%20med%20retningslinjer%20for%20diagnostikk,%20behandling%20og%20oppf%C3%B8lging.pdf/_/attachment/inline/06408501-5e87-4e0f-8249-d84877f4fca8:eea588d8f71754f56b2a83ab1a7355439f4fb43f/Analkreft%20-%20Nasjonalt%20handlingsprogram%20med%20retningslinjer%20for%20diagnostikk,%20behandling%20og%20oppf%C3%B8lging.pdf. Accessed 10 Aug 2020.

16.

The UK national guidance for IMRT in anal cancer. http://analimrtguidance.co.uk/national-anal-imrt-guidance-v3.pdf. Accessed 10 Aug 2020.

17.

Shakir R, Adams R, Cooper R, Downing A, Geh I, Gilbert D, et al. Patterns and predictors of relapse following Chemoradiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2020;106(2):329–39. https://doi.org/10.1016/j.ijrobp.2019.10.016.

18.

Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):97–110. https://doi.org/10.1007/s00259-017-3690-8.CrossRefPubMedPubMedCentral

19.

Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257–60. https://doi.org/10.1080/10428190903040048.CrossRefPubMed

20.

Nilsson MP, Nilsson ED, Johnsson A, Leon O, Gunnlaugsson A, Scherman J. Patterns of recurrence in anal cancer: a detailed analysis. Radiat Oncol. 2020;15(1):125.

21.

Garda AE, Navin PJ, Merrell KW, Martenson JA, Neben Wittich MA, Haddock MG, et al. Patterns of inguinal lymph node metastases in anal canal cancer and recommendations for elective clinical target volume (CTV) delineation. Radiother Oncol. 2020;149:128–33. https://doi.org/10.1016/j.radonc.2020.05.018.

22.

Dapper H, Schiller K, Munch S, Peeken JC, Borm K, Weber W, et al. Have we achieved adequate recommendations for target volume definitions in anal cancer? A PET imaging based patterns of failure analysis in the context of established contouring guidelines. BMC Cancer. 2019;19(1):742. https://doi.org/10.1186/s12885-019-5970-0.

23.

Paño B, Sebastià C, Buñesch L, Mestres J, Salvador R, Macías NG, et al. Pathways of lymphatic spread in male urogenital pelvic malignancies. Radiographics. 2011;31(1):135–60. https://doi.org/10.1148/rg.311105072.

24.

Dapper H, Oechsner M, Hirche C, Munch S, Sauter C, Borm K, et al. Dosimetric comparison of different radiation techniques (IMRT vs. 3-dimensional) of the "true" (deep) ano-inguinal lymphatic drainage of anal cancer patients. Radiat Oncol. 2018;13(1):227.CrossRef

25.

Bentzen AG, Guren MG, Wanderas EH, Frykholm G, Tveit KM, Wilsgaard T, et al. Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort. Int J Radiat Oncol Biol Phys. 2012;83(2):e173–80. https://doi.org/10.1016/j.ijrobp.2011.12.062.CrossRefPubMed

26.

Vilarino-Varela MJ, Taylor A, Rockall AG, Reznek RH, Powell ME. A verification study of proposed pelvic lymph node localisation guidelines using nanoparticle-enhanced magnetic resonance imaging. Radiother Oncol. 2008;89(2):192–6. https://doi.org/10.1016/j.radonc.2008.07.023.CrossRefPubMed

27.

Beets-Tan RGH, Lambregts DMJ, Maas M, Bipat S, Barbaro B, Curvo-Semedo L, et al. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol. 2018;28(4):1465–75. https://doi.org/10.1007/s00330-017-5026-2.CrossRefPubMed

28.

Gretschel S, Warnick P, Bembenek A, Dresel S, Koswig S, String A, et al. Lymphatic mapping and sentinel lymph node biopsy in epidermoid carcinoma of the anal canal. Eur J Surg Oncol. 2008;34(8):890–4. https://doi.org/10.1016/j.ejso.2007.11.013.CrossRefPubMed

Title: Patterns of pathologic lymph nodes in anal cancer: a PET-CT-based analysis with implications for radiotherapy treatment volumes
Authors: Anna Frennered
Jonas Scherman
Pamela Buchwald
Anders Johnsson
Hanna Sartor
Sophia Zackrisson
Elin Trägårdh
Martin P. Nilsson
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Metastasis
Radiotherapy
Anal Cancer
Anal Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08187-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Central neck lymph node metastasis in oral squamous cell carcinoma at the floor of mouth

Prediction of ipsilateral lateral cervical lymph node metastasis in papillary thyroid carcinoma: a combined dual-energy CT and thyroid function indicators study

The CRCbiome study: a large prospective cohort study examining the role of lifestyle and the gut microbiome in colorectal cancer screening participants

Ferroptosis-related gene signature predicts the prognosis in Oral squamous cell carcinoma patients

Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy

Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer